Observational studyThoracic cancer2020

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.

Takayuki Kishikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.